Xin Lang Cai Jing·2025-09-25 01:58Core Viewpoint - Nuo Cheng Jian Hua has seen a significant stock price increase, reflecting positive market sentiment and potential growth in the biopharmaceutical sector [1][2]. Company Overview - Nuo Cheng Jian Hua Pharmaceutical Co., Ltd. is based in Beijing and was established on November 3, 2015, with its IPO on September 21, 2022. The company focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [1]. - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and 0.15% each from testing and research services [1]. Stock Performance - As of September 25, Nuo Cheng Jian Hua's stock price rose by 5.02% to 29.49 CNY per share, with a total market capitalization of 52.039 billion CNY. The stock has increased by a cumulative 6.69% over the past three days [1]. - The trading volume on the same day was 63.42 million CNY, with a turnover rate of 0.81% [1]. Fund Holdings - The Huabao Pharmaceutical Biotech Mixed A Fund (240020) has increased its holdings in Nuo Cheng Jian Hua by 92,400 shares in the second quarter, bringing its total to 1.273 million shares, which constitutes 5.97% of the fund's net value [2]. - The fund has realized a floating profit of approximately 1.7949 million CNY today and 2.2404 million CNY during the three-day stock price increase [2]. Fund Manager Performance - The fund manager, Zhang Jintao, has been in position for 9 years and 338 days, managing a total asset size of 1.202 billion CNY. The best return during his tenure is 62.24%, while the worst is -12.53% [3].